Rheumatology has lagged behind oncology when it comes to the clinical application of personalized medicine, including biomarkers, genomics, and mutational analysis, but that is about to change according to the Organizers of the American College of Rheumatology (ACR) 2013 Annual Meeting, which will be held October 26 to 30 where Several keynote lectures, oral sessions, and posters will focus on bringing the molecular understanding of rheumatic diseases forward from the bench to the bedside.
Two key studies to be presented at a plenary session will explore triple therapy and whether this might be the best way to initiate treatment for early rheumatoid arthritis (RA).
Basic science chair John Varga, MD, cited several keynote lectures related to the theme of integrating basic science and clinical science. "Traditionally, our studies focused on mice or people. We realize now that the translational-clinical interface is key, and several of our talks reflect that," he said.
Atul Butte, MD, will lecture on data-mining huge amounts of genomic, genetic, and phenotypic information to determine which currently available drugs might work in which patient.
Three different speakers will discuss the omics of osteoarthritis — proteomics and genomics — and what we might have missed so far using systems biology to make treatment discoveries.
Another 3-speaker session on so-called inflammasomes in health and disease will explore how this inflammatory component of rheumatic diseases can be targeted with newer drugs.